1Angulo P. Nonalcoholic fatty liver disease [ J ]. N Engl J Med, 2002, 346(16) : 1221 - 1231.
2Park SH, Jeon WK, Kim SH, et al. Prevalence and risk factors of non - alcoholic fatty liver disease among Korean adults[ J]. J Gastroenterol Hepatol, 2006, 21 ( 1 ) : 138 - 143.
3Fan JG, Zhu J, Li X J, et al. Fatty liver and the metabolic syndrome among Shanghai adults [ J ]. J Gastroenterol Hepatol, 2005,20 (12): 1825 - 1832.
4Nannipieri M, Gonzales C, Baldi S, et al. Liver Enzymes, the Metabolic Syndrome, and Incident Diabetes: the Mexico City diabetes study[J]. Diabetes Care, 2005, 28 (7):1757- 1762.
6Vozarova B, Stefan N, Lindsay RS, et al. High alanine aminotransferase is associated with decreased hepatic insulin sensitivity and predicts the development of type 2 diabetes [ J]. Diabetes, 2002,51 (6) : 1889 - 1895.
7Sattar N, Scherbakova O, Ford I, et al. Elevated alanine aminotransferase predicts new - onset type 2 diabetes independently of classical risk factors, metabolic syndrome, and c - reactive protein in the west of scotland coronary prevention study[ J]. Diabetes, 2004, 53 ( 11 ) : 2855 - 2860.
8Hanley A J, Williams K, Festa A, et al. Insulin resistance atherosclerosis study. Elevations in markers of liver injury and risk of type 2 diabetes: the insulin resistance atherosclerosis study [ J ]. Diabetes, 2004, 53 (10) : 2623 - 2632.
9Browning JD, Szczepaniak LS, Dobbins R, et al. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity[ J]. Hepatology, 2004,40(6) : 1387 - 1395.
10Szczepaniak LS, Nurenberg P, Leonard D, et al. Magnetic resonance spectroscopy to measure hepatic triglyceride content: prevalence of hepatic steatosis in the general population[J]. Am J Physiol Endocrinol Metab, 2005,288 ( 2 ) : E462 - 468.
5Nannipieri M, Haffner SM, Ferrannini E, et al. Liver enzymes, the metabolic syndrome and incident diabetes: the Mexico City Diabetes Study. Diabetes Care,2005,28 : 1757-1762.
6Thomsen C, Becker U, Winkler K, et al. Quantification of liver fat using magnetic resonance spectroscopy. Magnelic Resonance Imaging, 1994, 12 : 487-495.
7Belfort R, Harrison SA, Brown K, et al. A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. N Engl J Med, 2006,355:2297-2307.
8Perseghin G, Lattuada G, De Cobelli F, et al. Habitual physical activity is associated with intrahepatic fat content in humans. Diabetes Care, 2007, 30:683-688.
9Petersen KF, Shulman GI. New insights into the pathogenesis of insulin resistance in humans using magnetic resonance spectroscopy. Obesity, 2006, 14 Suppl 1:34S-40S.
10Thomas EL, Hamilton G, Patel N, et al. Hepatic triglyceride content and its relation to body adiposity: a magnetic resonance imaging and proton magnetic resonance spectroscopy study. Gut, 2005 ,54 : 122-127.
